sotorasib

Details

Files
Generic Name:
sotorasib
Project Status:
Active
Therapeutic Area:
KRAS G12C-mutated advanced NSCLC
Manufacturer:
Amgen Canada Inc.
Brand Name:
Lumakras
Project Line:
Reimbursement Review
Project Number:
PC0300-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
​Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
Date NOC Issued:
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open21-Jul-22
Call for patient/clinician input closed12-Sep-22
Clarification:

- Patient input submission received from Lung Cancer Canada, Lung Health Foundation, and Canadian Cancer Survivor Network.

Submission received19-Aug-22
Submission accepted02-Sep-22
Review initiated06-Sep-22
Draft CADTH review report(s) provided to sponsor for comment20-Jul-23
Clarification:

- Submission temporarily suspended

- Additional information has been received and the temporary suspension of the review has been lifted

Deadline for sponsors comments31-Jul-23
CADTH review report(s) and responses to comments provided to sponsor31-Aug-23
Expert committee meeting (initial)13-Sep-23
Draft recommendation issued to sponsor27-Sep-23
Draft recommendation posted for stakeholder feedback05-Oct-23
End of feedback period20-Oct-23
Clarification:

- Reconsideration: major revisions requested by sponsor

Expert committee meeting14-Feb-24
Final recommendation posted19-Mar-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)14-Mar-24
CADTH review report(s) posted-